


AUTHOR QUERY FORM

 ELSEVIER	Journal: BETH Article Number: 198	Please e-mail or fax your responses and any corrections to: E-mail: corrections.essd@elsevier.spitech.com Fax: +1 61 9699 6721
---	--	--

Dear Author,

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof. Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list.

For correction or revision of any artwork, please consult <http://www.elsevier.com/artworkinstructions>.

Articles in Special Issues: Please ensure that the words ‘this issue’ are added (in the list and text) to any references to other articles in this Special Issue.

Uncited references: References that occur in the reference list but not in the text – please position each reference in the text or delete it from the list.	
Missing references: References listed below were noted in the text but are missing from the reference list – please make the list complete or remove the references from the text.	
Location in article	Query / remark Please insert your reply or correction at the corresponding line in the proof
Q1	Kindly provide the updated status of the reference.
Q2	Kindly provide the updated status of the reference.

Electronic file usage

Sometimes we are unable to process the electronic file of your article and/or artwork. If this is the case, we have proceeded by:

Scanning (parts of) your article
 Rekeying (parts of) your article
 Scanning the artwork

Thank you for your assistance.



Depression Vulnerability Moderates the Effects of Cognitive Behavior Therapy in a Randomized Controlled Trial for Smoking Cessation

Heather Schloss Kapson

David A. F. Haag

American University

Several clinical trials have tested the hypothesis that smoking cessation treatments with a mood management component derived from cognitive behavior therapy (CBT) for depression would be specifically effective for depression-vulnerable smokers, with mixed results. This trial addressed methodological concerns with some of the previous studies to clarify whether depression vulnerability does in fact moderate CBT smoking cessation outcome. The study compared 8-session group CBT with a time-matched comparison group condition in a sample of 100 cigarette smokers randomized to treatment condition. Each treatment group was led by one of 7 American University clinical psychology graduate students; therapists were crossed with treatment conditions. Outcome (7-day point prevalence abstinence) was evaluated 1 month and 3 months after quit date. Baseline self-reported depression vulnerability (sample median split on the Depression Proneness Inventory) moderated treatment response, such that more depression-prone smokers fared better in CBT whereas less depression-prone smokers fared better in the comparison condition. These results may have implications for determining when to use CBT components in smoking cessation programs.

TOBACCO USE CONTINUES TO be the leading cause of preventable death, disability, and illness in the United States (Centers for Disease Control [CDC], 2002), yet an estimated 20% of the United States adult population are current smokers, and of these smokers 78% smoke cigarettes daily (CDC, 2008). Between 1997 and 2001, smoking-related illnesses accounted for an estimated 438,000 premature deaths per year (CDC, 2005) and, additionally, they produced about \$157 billion in annual health-related economic costs (CDC, 2002).

A commonly reported motive for cigarette smoking is negative affect (Kassel, Stroud, & Paronis, 2003). Episodic negative affect also poses a high risk of relapse for those who have recently quit smoking (e.g., Shiffman, Paty, Gnys, Kassel, & Hickcox, 1996). Finally, chronic negative affect additionally plays a significant role in smoking. For example, depressed people are overrepresented among current smokers (e.g., Acierno, Kilpatrick, Resnick, Saunders, & Best, 1996), especially smokers high in nicotine dependence (e.g., Breslau, Kilbey, & Andreski, 1991). In a longitudinal epidemiological study of young adults, those with a history of major depression at baseline were substantially more likely than those without such a history to progress to daily smoking (Breslau, Peterson, Schultz, Chilcoat, & Andreski, 1998). Moreover, depressed people appear to have a harder time quitting smoking than do nondepressed smokers (Glassman, 1993); this applies even to individuals with low, subclinical levels of depressive symptoms (Niaura et al., 2001), to populations with depressed mood (Cinciripini et al., 2003), and to those with a lifetime history of at least one period of depressed mood or anhedonia lasting at least 2 weeks (Ziedonis et al.). A recent review

This research was supported by grant 2R15CA77732-02 from the National Cancer Institute.

We are grateful to Betty Malloy and Scott Parker for statistical consultation and to Kimberly Bowen, James Douglass, Lisa Fucito, Ramaris German, Debbie Glasofer, Angela Gray, Ozge Gurel, Meaghan Leddy, Colleen Sevilla, Sarah Skopek, Melissa Tanner, and Sarah Weisberg for assistance with conducting this study.

Address correspondence to David A. F. Haag, Ph.D., Department of Psychology, Asbury Building, American University, Washington, DC 20016-8062; e-mail: dhaaga@american.edu.

0005-7894/xx/xxx-xxx/\$1.00/0

© 2010 Association for Behavioral and Cognitive Therapies. Published by Elsevier Ltd. All rights reserved.

70 concluded that there may well be bidirectional
71 linkages between smoking and depression, such
72 that smoking can lead to depression or vice versa
73 (Ziedonis et al., 2008).

74 Based on such studies linking depression and
75 smoking, it has been hypothesized that adaptations
76 of psychotherapies for depression could be effective
77 in helping smokers learn alternate (nonsmoking)
78 means of coping with negative mood states and
79 thereby enhance the probability of successful
80 abstinence. Given that extensive research supports
81 the efficacy of cognitive behavior therapy (CBT;
82 Beck, Rush, Shaw, & Emery, 1979) in the treatment
83 of depression (e.g., Chambless et al., 1998), several
84 treatment programs that draw upon CBT have been
85 applied to the smoking cessation context (Brown,
86 2003). CBT for smokers in general has been shown
87 to be significantly more effective than minimal
88 cessation advice alone through 12-month follow-up
89 (e.g., Marks & Sykes, 2002).

90 Although few studies have been conducted of
91 psychosocial treatment for smokers *currently* experi-
92 encing major depression (for an exception, see Hall
93 et al., 2006), several investigators have tested the
94 hypothesis that CBT would be specifically effective
95 for smokers who are vulnerable to experiencing
96 depression. The premise is that such smokers would
97 especially benefit from learning healthier means of
98 managing negative mood states as a way of
99 maintaining abstinence. A history of major depres-
100 sion at baseline is not a significant independent
101 predictor of failing to benefit from smoking cessa-
102 tion treatment (Covey, Bombback, & Yan, 2006;
103 Hitsman, Borrelli, McChargue, Spring, & Niaura,
104 2003). Nevertheless, history of major depression
105 predicts depression in the wake of smoking cessation
106 treatment (Covey, Glassman, & Stetner, 1997), and
107 increases in depressive symptoms in response to
108 quitting smoking predict relapse (Burgess et al.,
109 2002), so it is plausible that smokers vulnerable to
110 depression could particularly benefit from mood
111 management skills addressed in CBT.

112 Clinical trials testing this moderator hypothesis
113 have yielded mixed results (Haaga, Hall, & Haas,
114 2006). In a sample of smokers with a history of
115 alcohol dependence, baseline depressive symptoms
116 interacted with treatment condition such that CBT
117 mood management techniques were helpful only
118 for smokers high in depressive symptoms (Patten,
119 Drews, Myers, Martin, & Wolter, 2002). Given
120 that baseline depressive symptom level is a signifi-
121 cant predictor of later incidence of major depres-
122 sion (Lewinsohn, Solomon, Seeley, & Zeiss, 2000),
123 this finding can be seen as consistent with the view
124 that CBT would be especially helpful for those
125 vulnerable to depression.

Most studies have instead operationalized vul- 126
nerability to depression as the presence of a history 127
of major depression. Hall, Muñoz, and Reus (1994) 128
found that a CBT group treatment added to a 129
standard health-education-based program signifi- 130
cantly outperformed the health education program 131
alone only for depression-vulnerable smokers, 132
operationalized in this study as having a history 133
of major depression. This result was replicated by 134
Hall et al. (1998). 135

However, a third clinical trial by the same 136
research group equated the two conditions for 137
therapy contact time and failed to replicate the 138
interaction of depression vulnerability and treat- 139
ment condition (Hall et al., 1996). In a study of 140
smokers with a history of alcohol dependence, CBT 141
significantly enhanced the efficacy of a behavioral 142
treatment based on nicotine fading and self- 143
monitoring, even with therapy contact time con- 144
trolled (Patten, Martin, Myers, Calfas, & Williams,
1998). However, all participants were positive for a 145
history of depression, so there is no way to 146
determine whether the beneficial impact of CBT 147
was specific to this group. 148
149

Finally, Brown and colleagues (2001) obtained a 150
specific effect for CBT with smokers with a history 151
of depression, but only if they had a history of 152
recurrent depression, not just a single previous 153
episode, suggesting that the method of measuring 154
depression vulnerability may influence results. This 155
effect was replicated in a secondary analysis of the 156
three Hall et al. (1994, 1996, 1998) clinical trials 157
cited earlier—CBT was more effective than a health 158
education comparison condition only for partici- 159
pants who had experienced at least two prior major 160
depressive episodes, not zero or one (Haas, Muñoz,
Humfleet, Reus, & Hall, 2004). 161
162

The Brown et al. (2001) and Haas et al. (2004) 163
results suggest that CBT may provide benefit 164
specifically for depression-vulnerable smokers and 165
that this effect might be found only at fairly high 166
levels of depression vulnerability. These results 167
would seem to bring welcome clarity to what has 168
been a confusing literature, but we believe addi- 169
tional research is needed. History of recurrent 170
major depression has itself proven inconsistent as 171
a moderator of CBT effects on smoking cessation. A 172
subsequent trial (Brown et al., 2007) did not find 173
CBT mood management treatment (relative to 174
standard CBT lacking the mood management 175
component, and crossed with either bupropion 176
or placebo) to be differentially effective among 177
those with a history of recurrent major depression, 178
though this nonreplication could have resulted 179
from limited statistical power. Of the 524 patients 180
randomized, only 16 had experienced multiple 181

182 prior depressive episodes. By the same token, this
 183 paucity of participants with multiple previous major
 184 depressive episodes is not just a statistical issue. It
 185 suggests that operationally defining depression
 186 vulnerability in this manner limits the vulnerable
 187 subgroup substantially in a typical smoking cessa-
 188 tion clinic and sets constraints on the practical utility
 189 of the findings for clinicians in such settings. Most
 190 importantly, it is not clear that this substantial
 191 winnowing of the population of smokers seeking to
 192 quit actually defines the depression-vulnerable
 193 subgroup in the most valid way possible.

194 Depression history (whether recurrent or not)
 195 may be an imprecise assessment of current vulner-
 196 ability to depression for a couple of reasons (Just,
 197 Abramson, & Alloy, 2001). There might be
 198 individuals who have yet to experience a major
 199 depressive episode because no suitably major
 200 stressor has occurred, even though they are actually
 201 high in depression vulnerability. Their depression
 202 vulnerability therefore would be underestimated if
 203 assessment is based only on the past occurrence of
 204 depressive episodes. Conversely, some smokers
 205 with histories of depression might no longer be
 206 highly vulnerable to depression as a result of
 207 enduring effects of interventions used in helping
 208 them recover in the first place.

209 To address the ambiguities associated with
 210 depression history as a measure of vulnerability in
 211 the research reported in this article, we measured
 212 current depression vulnerability with the Depres-
 213 sion Proneness Inventory (DPI; Alloy, Hartlage,
 214 Metalsky, & Abramson, 1987). To our knowledge,
 215 only two previous studies of cognitive-behavioral
 216 interventions for cigarette smokers have used the
 217 DPI as a predictor. A comparison of CBT with an
 218 intervention based upon motivational interviewing
 219 found no specific benefit of CBT for depression-
 220 vulnerable (high-DPI) smokers (Smith et al., 2001).
 221 However, this study differed from earlier CBT
 222 studies in that CBT and motivational interviewing
 223 were implemented as “step-up” treatments after an
 224 initial brief intervention and cessation attempt. It is
 225 not known whether results would be similar were
 226 these treatments implemented from the outset of the
 227 smoking cessation attempt. Conversely, Brandon
 228 et al. (1997) did report a selective effect of CBT for
 229 those high in depression proneness.

230 In view of the Brown et al. (2001) and Haas et al.
 231 (2004) findings indicating that a high level of
 232 depression vulnerability is necessary to show a
 233 selective benefit of CBT for smoking cessation, we
 234 did not predict that the DPI as a continuous variable
 235 in a sample unselected for depression vulnerability
 236 would moderate treatment response. Instead, we
 237 expected that high levels of depression vulnerability

would be necessary. Taxometric research conducted
 238 in a large sample of treatment-seeking smokers
 239 suggested that the DPI validly measures a taxonic
 240 construct of depression proneness (Strong, Brown,
 241 Kahler, Lloyd-Richardson, & Niaura, 2004). In the
 242 absence of precise guidance from the literature on
 243 what DPI score would be high enough to suggest
 244 probable membership in the “depression-prone”
 245 taxon,¹ we used our sample median split to select
 246 high and low depression-prone groups. 247

248 In summary, several studies have obtained
 249 interactive effects such that CBT mood manage-
 250 ment therapy is specifically effective for depression-
 251 vulnerable smokers, but findings have been incon-
 252 sistent, perhaps as a function of methods of
 253 measuring depression vulnerability. We therefore
 254 conducted a randomized clinical trial of CBT and a
 255 time-matched comparison treatment. We hypothe-
 256 sized that self-rated current depression proneness
 257 would interact with type of treatment in predicting
 258 abstinence outcomes through 3 months after quit
 259 date. CBT was expected to be more effective than
 260 the comparison condition for those above the
 261 sample median in depression proneness, but not
 262 for those below the median.

Method 263

PARTICIPANTS 264

265 Cigarette smokers were recruited from the
 266 Washington, DC, metropolitan area via newspaper
 267 advertisements, community fliers, public service
 268 announcements, advocacy organizations (e.g.,
 269 American Lung Association), online postings (e.g.,
 270 www.craigslist.org), and community and university
 271 health centers and hospitals. Advertisements soli-
 272 cited “smokers who want to quit” and indicated
 273 that help would be provided in the form of “group
 274 therapy sessions” or “group counseling”; there was
 275 no mention of mood management, cognitive
 276 behavior therapy, or depression proneness in the

¹ Strong et al. (2004) obtained an estimated base rate of 19% for the depression-prone taxon, which would imply that our characterization of those participants above the DPI sample median as highly depression-prone is overly liberal. However, (a) their taxometric analyses were based on a subset of DPI items, so it is not possible to reconstruct an exact total DPI score optimally separating the taxon members from nonmembers; (b) there was variability in the base rates estimated from different taxometric analyses, suggesting that more research is needed to pin this figure down more precisely; and (c) most importantly, their sample appears to have been less depression-prone than ours. Their sample obtained total DPI scores averaging 23.18 ($SD = 8.12$), whereas ours obtained a mean of 31.71 ($SD = 11.32$). As such, our above-the-median subsample (32 and higher) were all at least one standard deviation above the mean of the Strong et al. sample and therefore likely candidates for the depression-prone taxon even with only 19% of their sample qualifying as such.

277 ads. Cigarette smokers were enrolled in the
 278 program if they smoked at least 1 cigarette per
 279 day for the past 4 weeks, wanted to quit smoking,
 280 were fluent in English, were willing to be treated in
 281 a group setting, and were at least 18 years old. We
 282 set a low minimum smoking rate for eligibility
 283 (relative to some other trials that require, for
 284 instance, ≥ 10 cigarettes/day) because even very
 285 light smoking (1 to 4 cigarettes/day) has been linked
 286 in longitudinal epidemiological research with death
 287 from heart disease and with all-cause mortality
 288 (Bjartveit & Tverdal, 2005). As such, practice
 289 guidelines (USDHHS, 2008) recommend helping
 290 all tobacco users to quit.

291 Prospective participants were excluded and
 292 referred elsewhere if they were actively suicidal,
 293 on the premise that smoking cessation can be
 294 stressful and could exacerbate suicidal ideation.

295 One hundred participants (49 male, 51 female)
 296 both enrolled in the program and were randomized
 297 to a treatment condition. Four participants en-
 298 rolled in the program but dropped out prior to
 299 randomization; therefore, these participants were
 300 excluded from all remaining analyses. The sample
 301 size was determined by the number of eligible
 302 participants we were able to enroll and treat within
 303 the project funding period. The moderator effect of
 304 depression vulnerability in CBT smoking cessation
 305 studies has been erratic (see Introduction), and we
 306 did not have a confident a priori estimate of its
 307 effect size for sample size planning purposes. There
 308 were no interim analyses conducted during the
 309 study. Figure 1 summarizes the flow of participants
 310 from assessment to follow-up and analysis.

311 Participants ranged in age from 20 to 68 years
 312 ($M=42.85$, $SD=12.80$) and reported 9 to 21 years
 313 of education ($M=15.84$, $SD=2.46$). Participants
 314 were full-time employed (56%), part-time
 315 employed (14%), had a leave of absence or were
 316 unemployed (11%), were full-time students (8%),
 317 or retired (7%). Their annual household incomes
 318 ranged from less than \$10,000 to over \$200,000
 319 with the most common range (17%) being between
 320 \$50,000 to \$75,000.

321 A majority of participants were Caucasian
 322 (65%), whereas about one-quarter were African
 323 American (29%), with the remaining participants
 324 being Asian American (2%) or other races (3%).
 325 About one-tenth of the participants (9%) were of
 326 Hispanic ethnicity.

327 Pretreatment daily smoking rates varied widely,
 328 from 4 to 60 cigarettes, with an average just under a
 329 pack a day ($M=17.76$, $SD=8.34$). All participants
 330 reported having smoked for at least 1 year (mean
 331 years smoked= 23.49 , $SD=13.33$). Participants
 332 estimated that they tried to quit up to 50 times

before (median=3; 25th percentile=1; 75th per- 333
 centile=5). Their longest previous quit attempts 334
 ranged from less than 1 day to 6,120 days 335
 (median=90; 25th percentile=21; 75th percen- 336
 tile=270). The participants reported moderate 337
 nicotine dependence on the Fagerström Test for 338
 Nicotine Dependence ($M=4.66$, $SD=2.34$). 339

MEASURES 340

Suicidality was assessed with the Beck Scale for 341
 Suicide Ideation (BSI; Beck, Steer, & Ranieri, 342
 1988). The interviewer determined if significant 343
 suicidal ideation was present by following up on 344
 any positive responses on this questionnaire. If so, 345
 the participant was excluded from the study and 346
 referred elsewhere so that suicidal ideation could be 347
 addressed first. 348

Sample demographics and smoking history were 349
 assessed using brief, face valid questionnaires 350
 concerning age, gender, socioeconomic status, 351
 number of cigarettes smoked per day, number of 352
 past quit attempts, age at which the first cigarette 353
 was smoked, and the number of years that the 354
 participant smoked daily. 355

Nicotine dependence was measured with the 356
 Fagerström Test for Nicotine Dependence (FTND; 357
 Heatherton, Kozlowski, Frecker, & Fagerstrom, 358
 1991). This 6-item self-report has moderate 359
 internal consistency ($\alpha=.64$), satisfactory retest 360
 reliability over 2 to 3 weeks ($r=.88$), and positive 361
 correlations with cotinine levels ($r=.39$), with self- 362
 reports of “addiction” as a reason to smoke 363
 ($r=.53$), and with the number of years as a smoker 364
 ($r=.52$; Pomerleau, Carton, Lutzke, Flessland, & 365
 Pomerleau, 1994). Depression proneness was 366
 measured with the Depression Proneness Inventory 367
 (DPI; Alloy et al., 1987). The DPI is a 10-item self- 368
 report measure of vulnerability to depressive 369
 reactions to stress. The DPI is face valid, as the 370
 questions ask about proneness to depression (e.g., 371
 “Would your friends who know you best rate you 372
 as a person who easily becomes very depressed, 373
 sad, blue, or down in the dumps?”). Each item is 374
 rated on a 1 to 7 Likert-type scale, and the total 375
 DPI score is the sum of the item scores (i.e., 10 to 376
 70). The DPI is highly internally consistent 377
 ($\alpha=.90$ in nonclinical samples) and stable (1- 378
 month retest reliability $r=.88$; Alloy et al.). The 379
 DPI has correlated positively with current depres- 380
 sive symptoms and with number of past episodes 381
 of major or minor depressive disorder, but not 382
 with past episodes of anxiety disorders, mania, or 383
 drug and alcohol abuse (Alloy et al., 1987), 384
 supporting its specificity to depression proneness. 385
 A prospective study in an undergraduate sample 386
 supported its predictive validity in that DPI scores 387




FIGURE 1 The CONSORT E-Flowchart.

388 from the beginning of an introductory psychology
 389 course predicted increased depressive symptoms in
 390 the wake of a poor performance on a midterm
 391 examination above and beyond what could be
 392 predicted on the basis of Time 1 depression scores
 393 (Alloy et al.). In a clinical trial of smoking cessation
 394 methods, smokers who lapsed even once during the
 395 first week after a quit attempt had scored higher on
 396 the DPI at baseline than did those who maintained
 397 abstinence during the first week (Smith et al.,
 398 2001). In descriptive studies of smokers, DPI scores
 399 have been positively correlated with interview-

400 derived diagnoses of past major depression (Haaga
 401 et al., 2004) and with self-reported motivation to
 402 smoke in order to reduce negative mood (Brody
 403 et al., 2005). The association of DPI scores with
 404 past major depression was significant even after
 405 controlling for age, gender, and current depressive
 406 symptoms (Strong et al., 2004).

407 Smoking status was measured by self-report.
 408 When participants self-reported abstinence, expired
 409 air carbon monoxide (CO) was measured for
 410 verification purposes. Self-reports were collected
 411 in person at each treatment session after quit date

(sessions 5 through 8), at a posttreatment assessment 1 month after quit date, and by phone at 3 months after quit date. CO measurement always took place in person. If a participant reported abstinence by phone at the 3-month follow-up, an appointment was made for the participant to have their CO level measured in person. Our outcome measure was 7-day point prevalence abstinence, which entailed self-report of no use of tobacco products in the prior 7 days, as well as an expired air carbon monoxide (CO) reading of ≤ 8 parts per million (SRNT Subcommittee on Biochemical Verification, 2002). Seven-day point prevalence abstinence is the metric used in compiling results for the U.S. Department of Health and Human Services practice guideline (USDHHS, 2008). At each follow-up (1 month and 3 months post target quit date) there was one participant whose self-reported abstinence was disconfirmed by the CO reading, resulting in reclassification as a smoker.

Therapist adherence was measured by audio-taping each group treatment session. Masked raters who were familiar with the manuals developed for each condition subsequently rated a random sample of session tapes with respect to which therapy condition was being conducted, as a measure of the differentiability of the treatment conditions. Independently, additional raters aware of what condition was being conducted and of the session number rated a random sample of session tapes with regard to whether each of the topics or activities highlighted in the manual was actually addressed in the session.

444 PROCEDURE

445 *Design Overview, Research Setting, and Therapists*
 446 We randomized participants to one of two types of
 447 group smoking cessation treatment: (a) comparison
 448 condition: scheduled reduced smoking plus health
 449 education and (b) CBT condition: scheduled
 450 reduced smoking plus health education plus cognitive
 451 behavior therapy mood management procedures.
 452 Each condition consisted of eight sessions of
 453 90 minutes each. Treatment length was held
 454 constant so that any differences in outcome
 455 between the two conditions could not be attributed
 456 to extra treatment time (Haaga & Stiles, 2000).
 457 Each group consisted of approximately three to five
 458 participants with one of the seven graduate student
 459 therapists trained and then supervised weekly
 460 throughout the study. The supervisor (David
 461 Haaga, Ph.D.) is a licensed clinical psychologist
 462 with extensive training and experience in CBT and
 463 in training and supervising student therapists using
 464 these same treatments in a pilot study for this
 465 project (Thorndike, Friedman-Wheeler, & Haaga,
 466 2006). To avoid confounding general therapist skill

with treatment condition, therapists were crossed
 with condition. All assessments were conducted in
 the Department of Psychology at American University.
 Treatment group sessions were held in the
 psychotherapy training clinic housed within the
 same department.

473 *Assessment Sequence* 474

475 Smokers who called in response to study advertise-
 476 ments were screened over the phone. Those
 477 appearing likely to be eligible were scheduled for
 478 an in-person pretreatment assessment. Upon com-
 479 pletion of the 8-session intervention, each partici-
 480 pant was asked to complete an individual
 481 posttreatment assessment session approximately 1
 482 week after the treatment's conclusion (1 month
 483 after quit date) as well as a 3-month posttreatment
 484 follow-up appointment.

485 *Pretreatment assessment.* All assessments were
 486 conducted individually. Along with an appoint-
 487 ment reminder letter, participants received a self-
 488 monitoring form that requested the participant to
 489 monitor baseline levels of daily smoking and time
 490 spent asleep (information required for planning the
 491 details of scheduled reduced smoking). At the
 492 beginning of the pretreatment assessment, a
 493 trained master's or doctoral student completed
 494 written informed consent with the participant. The
 495 study was conducted in accordance with APA
 496 ethical standards and was approved by the
 497 American University IRB.

498 Participants were asked then to complete the
 499 Beck Suicidality Index (BSI). If any ideation was
 500 endorsed, the study staff conducted a clinical
 501 interview, provided hotline and referral informa-
 502 tion, and discussed the clinical management of the
 503 participant with the principal investigator. If the
 504 risk of suicide was none to minimal, the assessment
 505 session proceeded.

506 Participants were asked to provide a \$40.00
 507 deposit at the pretreatment assessment; \$20 was
 508 returned upon completion of the posttreatment
 509 assessment, and the remaining \$20 was returned
 510 upon the completion of the 3-month follow-up
 511 assessment.

512 In addition to smoking history, nicotine depen-
 513 dence, demographic, and depression vulnerability
 514 measures (as described in the Measures subsection),
 515 participants completed several questionnaires and
 516 computerized behavioral assessment tasks not
 517 relevant to this report (Schloss & Haaga, in press).

518 After individual pretreatment assessments were
 519 conducted with enough eligible participants to form
 520 a new group, and the group had been scheduled
 521 with a therapist, the project director would so

522 inform the principal investigator. The PI then used a
 523 random number table to assign the group to a
 524 treatment condition (CBT or comparison) and
 525 informed the project director and therapist of this
 526 assignment. No subject variables were used to
 527 stratify random assignment. During pretreatment
 528 assessment, therefore, both assessors and partici-
 529 pants were masked to treatment condition. During
 530 posttreatment and follow-up assessments such
 531 masking was not possible, but both participants
 532 and assessors remained masked to pretreatment
 533 depression proneness scores throughout the study,
 534 and smoking status reports were subject to bio-
 535 chemical corroboration and therefore should not be
 536 biased by knowledge of the treatment condition
 537 assignment.

538 *Posttreatment assessment.* Approximately 1
 539 week after completion of the final treatment session
 540 for both the comparison and CBT conditions (i.e., 1
 541 month after quit date), participants were scheduled
 542 for an individual posttreatment assessment session.
 543 Similar to the pretreatment assessment, participants
 544 were interviewed about their smoking status and
 545 then completed the same measures provided at the
 546 pretreatment assessment (excluding demographics
 547 and smoking history).

548 *Three-month follow-up.* Three months after the
 549 scheduled quit date, the study staff called group
 550 participants to inquire about their smoking status.
 551 If a participant indicated that she or he was
 552 abstinent, then that participant was scheduled to
 553 visit American University to have this report
 554 corroborated by an expired CO reading.

555 TREATMENTS

556 *Treatment: Common Components*

557 Each condition was guided by a treatment manual
 558 (available from the corresponding author) and
 559 incorporated an education component, as well as
 560 scheduled reduced smoking with a target quit date
 561 for all participants between the fourth and fifth
 562 therapy sessions. In each condition, all sessions
 563 were audiotaped for use in evaluating therapist
 564 adherence (see Results section).

565 *Education*

566 The psychoeducation component addressed nico-
 567 tine dependence and withdrawal symptoms. Parti-
 568 cipants were encouraged to analyze how the
 569 negative consequences of smoking (e.g., health
 570 risks, financial costs) applied to them in particular,
 571 along with what benefits they might obtain from
 572 smoking cessation. In the first session, participants'
 573 smoking histories were discussed, along with any
 574

575 previous quit attempts and where they might have
 576 gone awry. The education component also empha-
 577 sized the value of physical exercise, social support
 578 for nonsmoking, and self-reinforcement. Practical
 579 strategies for handling common temptation situa-
 580 tions were discussed in each group, including very
 581 concrete strategies for the target quit date such as
 582 discarding all tobacco products from one's home
 583 and reminding one's friends and family of the
 584 participant's commitment to nonsmoking. Each
 585 group addressed concerns about weight gain
 586 following cessation, identifying for instance low-
 587 calorie snacks that could be used when a participant
 588 wants something in her or his mouth instead of a
 589 cigarette and exercise plans feasible for each
 590 participant's lifestyle and current fitness. Finally,
 591 each condition included the option of using nicotine
 592 replacement, and participants in all groups received
 593 information about the nicotine patch. Nicotine
 594 replacement was monitored by therapists but was
 595 neither provided nor required as part of the study
 596 treatment. As part of the consent process, partici-
 597 pants had agreed not to participate in any other
 598 form of counseling for smoking cessation during the
 599 study, but nicotine replacement or medication
 600 treatment was allowed.

601 *Scheduled Reduced Smoking*

602 Participants in each treatment condition prepared
 603 for quit date using scheduled reduced smoking
 604 (Cinciripini, Wetter, & McClure, 1997). This
 605 method directs smokers to smoke only at designated
 606 times, on a predetermined schedule. The schedule
 607 gradually increases the amount of time between
 608 cigarettes and reduces the number of cigarettes
 609 smoked daily. In principle, adherence to such a
 610 schedule should make cessation easier because (a)
 611 gradual reduction of nicotine leads to diminished
 612 withdrawal symptoms after quit date, and (b)
 613 smoking at predetermined times should help break
 614 associations between the act of smoking and specific
 615 environmental or internal cues. Protocol instruc-
 616 tions for this component of treatment were adapted
 617 from a manual by Cinciripini, Baile, and Blalock
 618 (undated). Previous research showed increased 1-
 619 year abstinence in a CBT smoking cessation
 620 program among those who had been assigned to
 621 scheduled reduced smoking prior to quit date,
 622 compared to scheduled, nonreduced smoking,
 623 nonscheduled/nonreduced smoking (i.e., abrupt
 624 cessation), or nonscheduled reduced smoking (i.e.,
 625 number fading; Cinciripini et al., 1995).

626 *CBT Condition: The Unique Component*

627 The CBT mood management component of the
 628 program was based on Muñoz, Organista, and Hall
 629
 630

(1993), a manual tested in Hall et al. (1994) and Hall et al. (1996), as well as a protocol for “negative affect reduction counseling” by Brandon and colleagues (Herzog et al., 2002). Participants in CBT groups were taught to identify and evaluate negative cognitions and their impact on mood. They were asked to keep a record of their negative automatic thoughts and to evaluate the evidence bearing on these thoughts. Therapists taught participants to identify more adaptive, alternative thoughts when minimal evidence for the automatic thought existed. Participants were encouraged to intervene and cope with negative thoughts through cognitive restructuring instead of smoking. Toward the end of treatment, participants discussed with the help of the other group members how they would cope with their individual high-risk situations in the future (similar plans were made in the comparison condition, but not in relation to the use of mood management techniques).

Data Analysis

The hypothesized interaction of Treatment Condition X Depression Proneness was tested using both 1-month and 3-month point prevalence abstinence data within the Generalized Estimating Equations (GEE) framework, as recommended by Hall et al. (2001). GEE was implemented using SPSS 17.0, with robust covariance estimator, the Logit link function, and unstructured correlation matrix specified. The within-subject effect was time (1 month and 3 months after target quit date), and the dependent variable was abstinence. Predictor variables in the model were depression proneness (DPI sample median split: ≥ 32 vs. ≤ 31), treatment condition (CBT vs. comparison condition), and the interaction of depression proneness and treatment condition.

Results

BASELINE COMPARISONS

Demographics, depression proneness, and cigarette smoking variables from the pretreatment assessment are reported separately by treatment condition in Table 1. Our sample scored about one-third to one-half a standard deviation higher in depression proneness than a sample of smokers not seeking treatment ($M=26.00$, $SD=9.69$; Haaga et al., 2004) and a large adult sample consisting of a mix of current smokers, former smokers, and never-smokers ($M=28.56$, $SD=11.50$; Brody, Hamer, & Haaga, 2005). Demographics and smoking variables from pretreatment are reported separately by level of depression proneness in Table 2. Differences were nonsignificant, with two

exceptions. First, the highly depression prone were more likely to be Caucasian, and the less depression prone were more likely to be African American.² Second, as might be expected, the highly depression prone were more likely to have ever taken antidepressant medication. However, it should be noted that they did not exceed their low-depression-proneness counterparts in taking antidepressant medication as part of the current smoking cessation attempt, which was uncommon in our sample (6% of the high-DPI subsample, 10% of the low-DPI subsample).

PARTICIPANT FLOW AND ATTENDANCE AT ASSESSMENT AND THERAPY SESSIONS

Enrollment of participants in the study occurred from January 2005 through January 2007. Seventy-one percent of participants completed the 1-month post-quit-date assessment, and 82% completed the 3-month assessment. Eighty-five percent of the participants provided at least some follow-up data on smoking status.

Participants on average attended a little over one half of the 8 scheduled sessions. Comparison condition participants ($M=4.60$, $SD=2.81$) did not differ significantly from CBT participants ($M=4.35$, $SD=2.86$) in session attendance, $t(98)=0.43$, $p>.6$. About one eighth (12%) of participants refused treatment altogether, attending zero sessions. In some cases, these were people who had been kept waiting for a group to form, and by the time it started they had quit smoking, sought help elsewhere, or had their schedules change in such a way that they could not attend. With treatment refusers excluded, average attendance still did not differ significantly between the Comparison condition ($M=4.98$, $SD=2.57$) and CBT condition ($M=5.23$, $SD=2.27$), $t(86)=0.47$, $p>.6$.

IMPLEMENTATION OF INTERVENTIONS

All treatment sessions were audiotaped to facilitate clinical supervision as well as to assess the differentiability of the interventions and therapist adherence to the manualized interventions. With respect to differentiability, 15% of the session

² Despite this baseline difference in race as a function of depression proneness, race was not included as a covariate in our main analyses because (a) it was not prespecified as a covariate to include in planning the clinical trial, and adjusting for unplanned covariates because of baseline differences between groups may bias estimates of treatment effects (Altman, 1998; Raab, Day, & Sales, 2000); and (b) it was not predictive of outcome (focusing only on African Americans and Caucasians, the subgroups for whom we had enough participants to conduct an analysis, there was no significant relation between race and 3-month point prevalence abstinence, $X^2(1) = 1.16$, $p = .28$).

t1.1 Table 1

t1.2 Pretreatment Characteristics of Comparison Condition and CBT Participants

t1.3	Comparison (n=52)	CBT (n=48)	
t1.4	Demographics		
t1.5	Mean (SD) Years of Age	42.73 (12.88)	42.98 (12.85)
t1.6	% female	48	54
t1.7	Race: % Caucasian	60	71
t1.8	% African American or Black	32	25
t1.9	% Asian American	2	2
t1.10	% other or declined to answer	6	2
t1.11	Ethnicity: % Hispanic	12	6
t1.12	Employment: % employed fulltime	52	60
t1.13	Smoking: Current		
t1.14	Mean (SD) cigarettes per day	17.48 (9.88)	18.06 (6.35)
t1.15	Nicotine dependence (FTND Mean (SD))	4.67 (2.38)	4.65 (2.32)
t1.16	Smoking and Quitting History		
t1.17	Mean (SD) years of smoking	23.09 (13.21)	23.92 (13.58)
t1.18	Median (25%ile, 75%ile) prior quit attempts	3 (1.5, 5)	2 (1, 5)
t1.19	Median (25%ile, 75%ile) days longest prior quit	60 (18, 240)	105 (21, 292)
t1.20	Depression Proneness: Mean (SD) DPI total	31.54 (11.98)	31.90 (10.71)
t1.21	Ever Taken Antidepressant medication (%)	50	48

t1.22 Note. CBT=Cognitive Behavior Therapy; FTND=Fagerstrom Test for Nicotine Dependence; DPI=Depression Proneness Inventory.

728 audiotapes were selected at random for evaluation
 729 by one of two graduate student raters. The raters
 730 were familiar with the treatment manuals but were
 731 masked to what condition was intended for each
 732 session tape. They correctly identified the session as
 733 either CBT or comparison 100% of the time (30 of
 734 30 tapes).

735 A separate random sample of tapes (32 sessions)
 736 was selected for use in rating therapist adherence by
 737 one of two graduate student raters. For this task,
 738 the raters were made aware of the treatment

condition and session number and were familiar 739
 with the manuals. They completed a checklist of the 740
 topics to be addressed in each session (typically 6 or 741
 7 per session). Raters indicated that 100% of the 742
 intended topics were covered in the comparison 743
 condition sessions (and no CBT mood management 744
 content was detected in these sessions), with 99% of 745
 the intended topics covered in CBT sessions. All 746
 told, it appeared that raters could tell the conditions 747
 apart, and therapists were implementing essentially 748
 all of the methods called for by the protocol. 749

t2.1 Table 2

t2.2 Pretreatment Characteristics of High- and Low-Depression Prone Participants

t2.3	Low DPI (n=48)	High DPI (n=50)	t (96) (χ^2) [U]	p	
t2.4	Demographics				
t2.5	Mean (SD) Years of Age	43.48 (12.60)	41.82 (13.00)	0.64	.52
t2.6	% female	54	48	0.37	.54
t2.7	Race: % Caucasian	54	76	(5.91)	.02
t2.8	% African American	40	18		
t2.9	% Asian American	0	4		
t2.10	% other	6	2		
t2.11	Ethnicity: % Hispanic	6	12	(0.97)	.32
t2.12	Employment: % employed fulltime	56	54	(0.05)	.82
t2.13	Smoking: Current				
t2.14	Mean (SD) cigarettes per day	17.77 (6.07)	17.80 (10.23)	0.02	.99
t2.15	Nicotine dependence (FTND Mean (SD))	4.67 (2.14)	4.62 (2.56)	0.10	.92
t2.16	Smoking and Quitting History				
t2.17	Mean (SD) years of smoking	24.80 (13.19)	22.12 (13.57)	0.99	.32
t2.18	Median (25%ile, 75%ile) prior quit attempts	2 (1, 5)	3 (2, 5)	[883.5]	.13
t2.19	Median (25%ile, 75%ile) days longest prior quit	30 (21, 210)	112 (30, 364)	[811.5]	.16
t2.20	Ever taken antidepressant medication (%)	35	62	(6.92)	.008

t2.21 Note. FTND=Fagerstrom Test for Nicotine Dependence; Low DPI=Depression Proneness Inventory ≤ 31 at pretreatment; High DPI=Depression Proneness Inventory ≥ 32 at pretreatment; U=Mann-Whitney U test statistic.


750 ADVERSE EVENTS

751 The Beck Depression Inventory (BDI) was administered at each assessment and treatment session with the aim of tracking any increases in depressive symptoms during treatment. An increase (at any point) of 8 points or more on the BDI relative to the pretreatment assessment was flagged as an adverse event. This value falls within the range (e.g., 6.64 in McGlinchey, Atkins, & Jacobson, 2002; 11 in Persons, Bostrom, & Bertagnolli, 1999) of estimates of the magnitude of BDI change signifying statistically reliable deterioration. By this definition, nine participants in CBT and five in the comparison condition experienced increased depressive symptoms, which was not a significant difference across conditions, $\chi^2(df=1, N=100)=1.05, p=.30$. Also, one participant in each condition experienced an increase from pretreatment to posttreatment in daily smoking rate.

768 MODERATOR EFFECT OF DEPRESSION PRONENESS ON EFFICACY OF CBT

770 To test the hypothesized interaction of depression proneness and treatment condition, we conducted a GEE analysis as described in the Method section. The main effect of treatment condition was not significant, Wald chi-square ($df=1$)=0.82, $p>.3$. Likewise, the main effect of depression proneness was not significant, Wald chi-square ($df=1$)=0.45, $p>.5$. However, the interaction of treatment condition and depression proneness was a significant predictor of abstinence, Wald chi-square ($df=1$)=4.04, $p<.05$, $B=-2.01$ (95% confidence interval=-3.97 to -.05).

781 The interaction effect was in the predicted direction. To illustrate it, Table 3 and Figure 2 show the 7-day point prevalence abstinence rates at each follow-up. For example, at 3 months post-quit date, among those high in baseline depression proneness abstinence rates were higher in CBT (35% to 22%), whereas among those low in



788 **FIGURE 2** Seven-Day Point Prevalence Abstinence Percentages
789 in Each Treatment Condition for High and Low Depression-Prone
790 Smokers at Each Follow-up. Note. CBT = Cognitive Behavior
791 Therapy; High DPI = Depression Proneness Inventory ≥ 32 ; Low
792 DPI = Depression Proneness Inventory ≤ 31 .

788 depression proneness abstinence rates were higher 789
790 in the comparison condition (33% to 10%). 791

792 SECONDARY ANALYSES OF PROCESS VARIABLES 793

794 Collapsing across treatment condition, we exam- 795
796 ined in exploratory analyses a couple of potential 797
798 process predictors of 3-month abstinence. 799

798 *Session Attendance* 799

800 In the pilot study for this project, we had found that 801
802 participants who attended every treatment session 803
804 were significantly more likely to become abstainers 805
806 than were those who did not. This relation held in 807
808 the current study as well. Of the 16 participants 809
810 attending all 8 treatment sessions and providing 3- 811
812 month follow-up data, 50% ($n=8$) were 3-month 813
814 abstainers, compared to 18% (12 of 66) of those 815
816 who missed at least one session, chi-squared ($df=1$, 817
818 $N=82$)=7.07, $p<.01$, $\phi=.29$, $OR=4.5$ (95% 819
820 $CI=1.41$ to 14.39). This correlational finding does 821
822 not establish a causal effect of session attendance. It 823
824 could instead stem from reverse causality (e.g., those 825
826 who are getting more out of treatment are poten- 827
828 tially more likely to keep attending) or the effect of a 829

t3.1 Table 3
t3.2 Seven-Day Point Prevalence Abstinence Percentages in Each
t3.3 Treatment Condition for High and Low Depression-Prone
t3.4 Smokers at Each Follow-up

		CBT	Comparison	OR	
<i>One Month After Quit Date</i>					
t3.5	Depression Proneness	High	41	29	1.68
t3.6		Low	16	50	0.19
<i>Three Months After Quit Date</i>					
t3.9	Depression Proneness	High	35	22	1.94
t3.10		Low	10	33	0.31

t3.11 Note. CBT=Cognitive Behavior Therapy; OR=odds ratio for efficacy of CBT within each level of depression proneness (High=Depression Proneness Inventory ≥ 32 ; Low=Depression Proneness Inventory ≤ 31).

810 third variable (e.g., high motivation to quit smoking
811 could lead to both perfect session attendance and
812 successful abstinence).

813 *Adjunctive Use of Nicotine Replacement*

814 About one-third of participants (34%) reported at
815 any point having used nicotine replacement pro-
816 ducts. There was no difference between treatment
817 conditions, $X^2 (df=1, N=96)=0.63, p>.4$, or
818 between groups defined by median split on the
819 DPI, $X^2 (df=1, N=94)=0.05, p>.8$, in the fre-
820 quency of using nicotine replacement. Approxi-
821 mately one-third (10 of 31, 32%) of participants
822 who used nicotine replacement were abstinent at
823 the 3-month follow-up, a proportion that did not
824 differ significantly from the abstinence rate (10 of
825 50, 20%) among those who chose not to use
826 nicotine replacement, $X^2 (df=1, N=80)=1.55,$
827 $p>.2$.

829 Discussion

830 In a randomized controlled trial of small-group
831 smoking cessation interventions, self-rated depres-
832 sion proneness moderated response to CBT. In
833 particular, abstinence was more likely among the
834 highly depression-prone if they were assigned to a
835 treatment condition incorporating the use of
836 cognitive restructuring as a mood management
837 method, whereas less depression-prone smokers
838 fared better if assigned to a time-matched compar-
839 ison condition omitting the cognitive restructuring
840 component and mood management emphasis. Both
841 conditions involved scheduled reduced smoking
842 prior to quit date, health education, an emphasis on
843 social support seeking inside and outside the group,
844 planning for challenges in the early days after
845 quitting, and other standard psychosocial methods.

846 It seems likely that CBT mood management
847 treatment helps depression-vulnerable smokers by
848 giving them other means, aside from smoking, to
849 respond to the negative mood states that they often
850 experience and that prompt relapse for some recent
851 quitters. An issue for future empirical research is to
852 pin down the nature of this mediating mechanism
853 of the effects of CBT for depression-vulnerable
854 smokers. Descriptive research has implicated poor
855 coping skills as a correlate of depression vulnera-
856 bility among smokers (Haaga et al., 2004; Kahler,
857 Brown, Lloyd-Richardson, & Niaura, 2003;
858 Rabois & Haaga, 1997), but to date there is no
859 evidence that CBT has a specific effect in improving
860 these coping skills (Thorndike et al., 2006). This
861 possibility, and other candidate mechanisms,
862 should be evaluated in samples large enough to
863 support powerful analyses of mediation effects for
864 treatments exerting specific benefits only for a

865 subgroup (e.g., the more depression-prone) of
866 participants, in other words “mediated modera-
867 tion” (Muller, Judd, & Yzerbyt, 2005).

868 Conversely, for less depression-vulnerable smo-
869 kers, inclusion of mood management techniques
870 derived from CBT for depression might be some-
871 thing of a waste of time, addressing a concern that
872 does not really apply to them. In this regard, it is
873 important to note that the treatment conditions in
874 this study were time-matched, so it is possible that
875 the common components (health education, social
876 support, weight management, self-reinforcement,
877 etc.) could have received shorter shrift in the CBT
878 condition, to the detriment of the low-depression-
879 vulnerable smokers. No topics or techniques were
880 eliminated altogether from the CBT condition, but
881 a given topic (e.g., brainstorming strategies for
882 rewarding oneself for achieving abstinence goals)
883 might have been addressed at greater length in
884 groups in the comparison condition given that they
885 did not need to incorporate cognitive restructuring
886 practice/instruction in sessions. This concern is
887 particularly salient in our study given that (a) par-
888 ticipants who began treatment averaged approxi-
889 mately 5 sessions attended, and (b) perfect
890 attendance (8 of 8 sessions) was associated with
891 better outcomes. Thus, it is possible that more
892 treatment time is better and that the treatment dose
893 for many of our participants was not high, so any
894 time spent on a skill or topic a given participant
895 does not need (e.g., mood management for those
896 not prone to depression) is potentially problematic.

897 This issue poses a methodological challenge for
898 any study employing a dismantling design to try to
899 isolate the impact of a subset of treatment
900 techniques. If treatment time is held constant, as
901 in this study and in, for one example, a well-known
902 dismantling investigation of cognitive therapy of
903 depression (Jacobson et al., 1996), then the
904 common treatment component(s) may be weaker
905 in the experimental condition(s) incorporating
906 extra components. On the other hand, if that
907 problem is prevented by letting the combination
908 treatment run longer, as in Hall et al. (1994), then
909 additional treatment time per se becomes a viable
910 rival hypothesis for the effects of the isolated
911 treatment component.

912 Our findings are consistent with several previous
913 demonstrations of an interaction of depression
914 vulnerability with treatment condition in the study
915 of CBT for smokers (e.g., Brandon et al., 1997;
916 Brown et al., 2001; Haas et al., 2004; Hall et al.,
917 1994; Hall et al., 1998; Patten et al., 2002) but are
918 inconsistent with other reports of failures to
919 replicate the effect (e.g., Brown et al., 2007; Hall
920 et al., 1996). As described in the Introduction, we

921 believe that measurement issues may be relevant in
 922 determining these inconsistencies and believe that
 923 our reliance on self-reported current depression
 924 proneness rather than history of depression is a
 925 methodological strength of this study. Future
 926 research could evaluate the role of measurement
 927 method more definitively either by (a) quantitative-
 928 ly reviewing the full set of studies of depression
 929 vulnerability as a moderator of CBT effects for
 930 smokers and determining whether effects are
 931 significantly heterogeneous and, if so, whether
 932 partitioning the studies by type of depression
 933 vulnerability measure reduces that heterogeneity,
 934 or (b) conducting a large prospective study incor-
 935 porating multiple measures of depression vulnera-
 936 bility. A prospective-study methodology for
 937 resolving measurement issues in this area would
 938 have the advantage of determining whether our
 939 results are replicable and whether the DPI score
 940 (≥ 32) range selected in our sample on the basis of a
 941 median split is optimal as a marker of high
 942 vulnerability.

943 METHODOLOGICAL ISSUES

944 The results reported in this manuscript should be
 945 interpreted in light of the strengths and limitations
 946 of the study. On the positive side, participants were
 947 randomly assigned to conditions, and self-reported
 948 abstinence was corroborated by expired air CO
 949 levels. Treatment conditions were differentiable by
 950 coders unaware of the intended condition, and
 951 therapist adherence ratings were high.

952 Methodological limitations include a modest
 953 sample size for studying moderator effects, making
 954 replication especially important. Interactions
 955 between patient variables and treatment conditions
 956 are potentially important both theoretically and
 957 practically (e.g., Latimer, Katulak, Mowad, &
 958 Salovey, 2005) but are often small effects and
 959 therefore somewhat erratic in individual studies
 960 (Noar, Benac, & Harris, 2007). Also, while
 961 differentiability of treatments was assured, and
 962 therapist adherence measured, there was no mea-
 963 sure of therapist competence, leaving open the
 964 question of whether the CBT and comparison
 965 conditions were equally well executed.

966 Finally, the follow-up duration of 3 months after
 967 quit date was relatively brief. Longer term follow-
 968 ups may well have yielded lower 7-day point
 969 prevalence abstinence rates. For example, in both
 970 CBT conditions (one combined with bupropion,
 971 the other with placebo) in Brown et al. (2007),
 972 abstinence rates at 12 months were 18%. At the 2-
 973 month follow-up, the CBT abstinence rates were
 974 25% and 26%, quite similar to the rate in this study
 975 at 3 months (see Table 3). Although a longer

976 duration of follow-up would likely have lowered
 977 our absolute abstinence rates, we do not have a
 978 conceptual basis for predicting that longer follow-
 979 up would have eliminated the moderator effect we
 980 observed.

981 Conclusion

982 Thus, numerous questions remain for future re-
 983 search, such as the mediating mechanisms for, and
 984 durability at longer follow-ups of, the moderator
 985 effect of depression vulnerability on the efficacy of
 986 CBT for smokers. However, if future studies
 987 corroborate our findings, the results have straight-
 988 forward clinical implications.

989 Most importantly, practitioners may be able to
 990 enhance smoking cessation outcomes by measuring
 991 depression proneness at baseline and incorporating
 992 CBT mood management interventions *only* for the
 993 highly depression-vulnerable. If our findings prove
 994 replicable, the practical effects of such a strategy
 995 would be important. Considering 3-month point
 996 prevalence data (Table 3), a clinician matching
 997 interventions to depression proneness (CBT for
 998 highly depression-prone, comparison for low
 999 depression-prone) could anticipate success with
 1000 34% of smokers, whereas a mismatching strategy
 1001 would yield 16% successes, and a random strategy
 1002 (use CBT or comparison without regard to
 1003 depression proneness) 25% successes. Deliberate
 1004 mismatching is unlikely as a real-world scenario,
 1005 but matching relative to random allocation would
 1006 result in important gains given the large population
 1007 of smokers. The number-needed-to-treat for this
 1008 difference (34% vs. 25%) is 11, meaning that for
 1009 every 11 smokers treated, there would be one
 1010 additional favorable result (abstinence in this case).

1011 Also, clinicians could highlight for cigarette
 1012 smokers that, while causal inferences are not
 1013 warranted on the basis of our correlational findings,
 1014 high engagement in the treatment (operationalized
 1015 in our study as perfect attendance at 8 sessions of
 1016 treatment) is at least associated with a substantially
 1017 greater likelihood of successful abstinence.

1018 References

- 1019 Acierno, R. A., Kilpatrick, D. G., Resnick, H. S., Saunders, B. E.,
 1020 & Best, C. L. (1996). Violent assault, posttraumatic stress
 1021 disorder, and depression: Risk factors for cigarette use
 1022 among adult women. *Behavior Modification*, 20, 363–384.
 1023 Alloy, L. B., Hartlage, S., Metalsky, G. I., & Abramson, L. Y.
 1024 (1987). *The Depression Proneness Inventory: A brief, face-*
 1025 *valid scale of vulnerability to depressive reactions in*
 1026 *response to stress*. Unpublished manuscript, Temple Uni-
 1027 versity Philadelphia, PA.
 1028 Altman, D. G. (1998). Adjustment for covariate imbalance. In P.
 1029 Armitage & T. Colton (Eds.), *Encyclopedia of biostatistics*
 1030 (pp. 1000–1005). New York: John Wiley & Sons.

- 1031 Beck, A. T., Rush, A. J., Shaw, B. F., & Emery, G. (1979).
1032 *Cognitive therapy of depression*. New York: Guilford Press.
- 1033 Beck, A., Steer, R., & Ranieri, W. (1988). Scale for suicide
1034 ideation: Psychometric properties of a self-report version.
1035 *Journal of Clinical Psychology, 44*, 499–505.
- 1036 Bjartveit, K., & Tverdal, A. (2005). Health consequences of
1037 smoking 1–4 cigarettes per day. *Tobacco Control, 14*,
1038 315–320.
- 1039 Brandon, T. H., Juliano, L. M., Copeland, A. L., Collins, B. N.,
1040 Quinn, E. P., & Lazev, A. B. (1997, April). *Matching*
1041 *smokers to treatment based on negative affectivity*. Paper
1042 presented at the annual meeting of the Society of Behavioral
1043 Medicine. San Francisco, CA.
- 1044 Breslau, N., Kilbey, M., & Andreski, P. (1991). Nicotine
1045 dependence, major depression, and anxiety in young adults.
1046 *Archives of General Psychiatry, 48*, 1069–1074.
- 1047 Breslau, N., Peterson, E., Schultz, L., Chilcoat, H., & Andreski,
1048 P. (1998). Major depression and stages of smoking: A
1049 longitudinal investigation. *Archives of General Psychiatry, 55*,
1050 161–166.
- 1051 Brody, C. L., Hamer, D. H., & Haaga, D. A. F. (2005).
1052 Depression vulnerability, cigarette smoking, and the
1053 serotonin transporter gene. *Addictive Behaviors, 30*,
1054 557–566.
- 1055 Brown, R. A. (2003). Comorbidity treatment: Skills training for
1056 coping with depression and negative moods. In D. B.
1057 Abrams, R. Niaura, R. A. Brown, K. M. Emmons, M. G.
1058 Goldstein, & P. M. Monti (Eds.), *The tobacco dependence*
1059 *treatment handbook: A guide to best practices*
1060 (pp. 178–229). New York: Guilford Press.
- 1061 Brown, R., Kahler, C., Niaura, R., Abrams, D., Sales, S.,
1062 Ramsey, S., Goldstein, M., Burgess, E., & Miller, I. (2001).
1063 Cognitive-behavioral treatment for depression in smoking
1064 cessation. *Journal of Consulting and Clinical Psychology, 69*,
1065 471–480.
- 1066 Brown, R. A., Niaura, R., Lloyd-Richardson, E. E., Strong,
1067 D. R., Kahler, C. W., Abrantes, A. M., Abrams, D., &
1068 Miller, I. W. (2007). Bupropion and cognitive-behavioral
1069 treatment for depression in smoking cessation. *Nicotine*
1070 *& Tobacco Research, 7*, 721–730.
- 1071 Burgess, E. S., Kahler, C. W., Niaura, R., Abrams, D. B.,
1072 Goldstein, M. G., & Miller, I. W. (2002). Patterns of change
1073 in depressive symptoms during smoking cessation: Who's at
1074 risk for relapse? *Journal of Consulting and Clinical*
1075 *Psychology, 70*, 356–361.
- 1076 Centers for Disease Control and Prevention. (2002). Annual
1077 smoking-attributable mortality, years of potential life lost,
1078 and economic costs—United States, 1995–1999. *Morbidity*
1079 *and Mortality Weekly Report, 51*, 300–303.
- 1080 Centers for Disease Control and Prevention. (2005). Annual
1081 smoking-attributable mortality, years of potential life lost,
1082 and economic costs—United States, 1997–2001. *Morbidity*
1083 *and Mortality Weekly Report, 54*, 625–628.
- 1084 Centers for Disease Control and Prevention. (2008). Cigarette
1085 smoking among adults—United States, 2007. *Morbidity and*
1086 *Mortality Weekly Report, 57*, 1221–1226.
- 1087 Chambless, D. L., Baker, M. J., Baucom, D. H., Beutler, L. E.,
1088 Calhoun, K. S., Crits-Christoph, P., Daiuto, A., DeRubeis,
1089 R., Dettweiler, J., Haaga, D. A. F., Johnson, S. B., McCurry,
1090 S., Mueser, K. T., Pope, K. S., Sanderson, W. C., Shoham,
1091 V., Stickle, T., Williams, D. A., & Woody, S. R. (1998).
1092 Update on empirically validated therapies, II. *The Clinical*
1093 *Psychologist, 51*, 3–16.
- 1094 Cinciripini, P. M., Baile, W. F., & Blalock, J. (undated). *Project*
1095 *CASSI: Smoking cessation study*. University of Texas M. D.
1096 Anderson Cancer Center. Department of Behavioral Science.
1097 Tobacco Research & Treatment Program.
- Cinciripini, P. M., Lapitsky, L., Seay, S., Wallfisch, A.,
Kitchens, K., & Vunakis, H. V. (1995). The effects of
smoking schedules on cessation outcome: Can we improve
on common methods of gradual and abrupt nicotine
withdrawal? *Journal of Consulting and Clinical Psychology, 63*,
388–399.
- Cinciripini, P. M., Wetter, D. W., Fouladi, R. T., Blalock, J. A.,
Carter, B. L., Cinciripini, L. G., & Baile, W. F. (2003). The
effects of depressed mood on smoking cessation: Mediation
by postcessation self-efficacy. *Journal of Consulting and*
Clinical Psychology, 71, 292–301.
- Cinciripini, P. M., Wetter, D. W., & McClure, J. B. (1997).
Scheduled reduced smoking: Effects on smoking abstinence
and potential mechanisms of action. *Addictive Behaviors, 19*,
13–22.
- Covey, L. S., Bombback, A., & Yan, G. W. Y. (2006). History of
depression and smoking cessation: A rejoinder. *Nicotine &*
Tobacco Research, 8, 315–319.
- Covey, L. S., Glassman, A. H., & Stetner, F. (1997). Major
depression following smoking cessation. *American Journal*
of Psychiatry, 154, 263–265.
- Glassman, A. (1993). Cigarette smoking: Implications for
psychiatric illness. *American Journal of Psychiatry, 150*,
546–553.
- Haaga, D. A. F., Hall, S. M., & Haas, A. (2006). Participant
factors in treating substance use disorders. In L. G.
Castonguay & L. E. Beutler (Eds.), *Principles of*
therapeutic change that work (pp. 275–292). Oxford:
Oxford University Press.
- Haaga, D. A. F., & Stiles, W. B. (2000). Randomized clinical
trials in psychotherapy research: Methodology, design, and
evaluation. In C. R. Snyder & R. E. Ingram (Eds.),
Handbook of psychological change: Psychotherapy pro-
cesses and practices for the 21st century (pp. 14–39). New
York: Wiley.
- Haaga, D. A. F., Thorndike, F. P., Friedman-Wheeler, D. G.,
Pearlman, M. Y., & Wernicke, R. A. (2004). Cognitive
coping skills and depression vulnerability among cigarette
smokers. *Addictive Behaviors, 29*, 1109–1122.
- Haas, A. L., Muñoz, R. F., Humfleet, G. L., Reus, V. I., & Hall,
S. M. (2004). Influences of mood, depression history, and
treatment modality on outcomes in smoking cessation.
Journal of Consulting and Clinical Psychology, 72, 563–570.
- Hall, S. M., Delucchi, K. L., Velicer, W. F., Kahler, C. W.,
Ranger-Moore, J., Hedeker, D., Tsoh, J. Y., & Niaura, R.
(2001). Statistical analysis of randomized trials in tobacco
treatment: Longitudinal designs with dichotomous outcome.
Nicotine & Tobacco Research, 3, 193–202.
- Hall, S., Muñoz, R., & Reus, V. (1994). Cognitive-behavioral
intervention increases abstinence rates for depressive-history
smokers. *Journal of Consulting and Clinical Psychology, 62*,
141–146.
- Hall, S., Muñoz, R., Reus, V., Sees, K., Duncan, C., Humfleet,
G., & Hartz, D. (1996). Mood management and nicotine
gum in smoking treatment: A therapeutic contact and
placebo-controlled study. *Journal of Consulting and Clinical*
Psychology, 64, 1003–1009.
- Hall, S., Reus, V., Muñoz, R., Sees, K., Humfleet, G., Hartz, D.,
Frederick, S., & Triffleman, E. (1998). Nortriptyline and
cognitive-behavioral therapy in the treatment of cigarette
smoking. *Archives of General Psychiatry, 55*, 683–690.
- Hall, S. M., Tsoh, J. Y., Prochaska, J. J., Eisendrath, S., Rossi,
J. S., Redding, C. A., Rosen, A. B., Meisner, M., Humfleet,
G. L., & Gorecki, J. A. (2006). Treatment for cigarette
smoking among depressed mental health outpatients: A
randomized clinical trial. *American Journal of Public*
Health, 96, 1808–1814.

- 1165 Heatherton, T., Kozlowski, L., Frecker, R., & Fagerström, K. (1991). The Fagerström Test for Nicotine Dependence: A
1166 revision of the Fagerström Tolerance Questionnaire. *British*
1167 *Journal of Addiction*, 86, 1119–1127.
- 1169 Herzog, T. A., Lazev, A. B., Irvin, J. E., Juliano, L. M.,
1170 Greenbaum, P. E., & Brandon, T. H. (2002). Testing for
1171 group membership effects during and after treatment: The
1172 example of group therapy for smoking cessation. *Behavior*
1173 *Therapy*, 33, 29–43.
- 1174 Hitsman, B., Borrelli, B., McChargue, D. E., Spring, B., &
1175 Niaura, R. (2003). History of depression and smoking
1176 cessation outcome: A meta-analysis. *Journal of Consulting*
1177 *and Clinical Psychology*, 71, 657–663.
- 1178 Jacobson, N. S., Dobson, K. S., Truax, P. A., Addis, M. E.,
1179 Koerner, K., Gollan, J. K., Gortner, E., & Prince, S. E.
1180 (1996). A component analysis of cognitive-behavioral
1181 treatment for depression. *Journal of Consulting and Clinical*
1182 *Psychology*, 64, 295–304.
- 1183 Just, N., Abramson, L. Y., & Alloy, L. B. (2001). Remitted
1184 depression studies as tests of the cognitive vulnerability
1185 hypotheses of depression onset: A critique and conceptual
1186 analysis. *Clinical Psychology Review*, 21, 63–83.
- 1187 Kahler, C. W., Brown, R. A., Lloyd-Richardson, E. E., &
1188 Niaura, R. (2003). History of major depressive disorder
1189 among smokers in cessation treatment: Associations with
1190 dysfunctional attitudes and coping. *Addictive Behaviors*, 28,
1191 1033–1047.
- 1192 Kassel, J. D., Stroud, L. R., & Paronis, C. A. (2003). Smoking,
1193 stress, and negative affect: Correlation, causation, and
1194 context across stages of smoking. *Psychological Bulletin*,
1195 129, 270–304.
- 1196 Latimer, A. E., Katulak, N. A., Mowad, L., & Salovey, P.
1197 (2005). Motivating cancer prevention and early detection
1198 behaviors using psychologically tailored messages. *Journal*
1199 *of Health Communication*, 10, 137–155.
- 1200 Lewinsohn, P. M., Solomon, A., Seeley, J. R., & Zeiss, A.
1201 (2000). Clinical implications of “subthreshold” depressive
1202 symptoms. *Journal of Abnormal Psychology*, 109, 345–351.
- 1203 Marks, D. F., & Sykes, C. M. (2002). Randomized controlled
1204 trial of cognitive behavioural therapy for smokers living in a
1205 deprived area of London: Outcome at one-year follow-up.
1206 *Psychology Health & Medicine*, 7, 17–24.
- 1207 McGlinchey, J. B., Atkins, D. C., & Jacobson, N. S. (2002).
1208 Clinical significance methods: Which one to use and how
1209 useful are they? *Behavior Therapy*, 33, 529–550.
- 1210 Muller, D., Judd, C. M., & Yzerbyt, V. Y. (2005). When
1211 moderation is mediated and mediation is moderated.
1212 *Journal of Personality and Social Psychology*, 89, 852–863.
- 1213 Muñoz, R., Organista, K., & Hall, S. (1993). *Mood manage-*
1214 *ment training to prevent smoking relapse: A cognitive-*
1215 *behavioral treatment manual*. San Francisco: University of
1216 California, San Francisco.
- 1217 Niaura, R., Britt, D. M., Shadel, W. G., Goldstein, M., Abrams,
1218 D., & Brown, R. (2001). Symptoms of depression and
1219 survival experience among three samples of smokers trying
1220 to quit. *Psychology of Addictive Behaviors*, 15, 13–17.
- 1221 Noar, S. M., Benac, C. N., & Harris, M. S. (2007). Does tailoring
1222 matter? Meta-analytic review of tailored print health
1223 behavior change interventions. *Psychological Bulletin*, 133,
1224 673–693.
- 1225 Patten, C. A., Drews, A. A., Myers, M. G., Martin, J. E., &
1226 Wolter, T. D. (2002). Effect of depressive symptoms on
1227 smoking abstinence and treatment adherence among smok-
1228 ers with a history of alcohol dependence. *Psychology of*
1229 *Addictive Behaviors*, 16, 135–142.
- 1230 Patten, C., Martin, J., Myers, M., Calfas, K., & Williams, C.
1231 (1998). Effectiveness of cognitive-behavioral therapy for
1232 smokers with histories of alcohol dependence and depres-
1233 sion. *Journal of Studies on Alcohol*, 59, 327–335.
- 1234 Persons, J. B., Bostrom, A., & Bertagnolli, A. (1999). Results of
1235 randomized controlled trials of cognitive therapy for
1236 depression generalize to private practice. *Cognitive Therapy*
1237 *and Research*, 23, 535–548.
- 1238 Pomerleau, C., Carton, S., Lutzke, M., Flessland, K., &
1239 Pomerleau, O. (1994). Reliability of the Fagerström
1240 Tolerance Questionnaire and the Fagerström Test for
1241 Nicotine Dependence. *Addictive Behaviors*, 19, 33–39.
- 1242 Raab, G. M., Day, S., & Sales, J. (2000). How to select
1243 covariates to include in the analysis of a clinical trial.
1244 *Controlled Clinical Trials*, 21, 330–342.
- 1245 Rabois, D., & Haaga, D. A. F. (1997). Cognitive coping, history
1246 of depression, and cigarette smoking. *Addictive Behaviors*,
1247 22, 789–796.
- 1248 Schloss, H. M., & Haaga, D. A. F. (in press). Interrelating
1249 behavioral measures of distress tolerance with self-reported
1250 experiential avoidance. *Journal of Rational-Emotive &*
1251 *Cognitive-Behavior Therapy*.
- 1252 Shiffman, S., Paty, J. A., Gnys, M., Kassel, J. A., & Hickcox, M.
1253 (1996). First lapses to smoking: Within-subjects analysis of
1254 real-time reports. *Journal of Consulting and Clinical*
1255 *Psychology*, 64, 366–379.
- 1256 Smith, S. S., Jorenby, D. E., Fiore, M. C., Anderson, J. E., Mielke,
1257 M. M., Beach, K. E., Piasecki, T. M., & Baker, T. B. (2001).
1258 Strike while the iron is hot: Can stepped-care treatments
1259 resurrect relapsing smokers? *Journal of Consulting and*
1260 *Clinical Psychology*, 69, 429–439.
- 1261 SRNT Subcommittee on Biochemical Verification. (2002).
1262 Biochemical verification of tobacco use and cessation.
1263 *Nicotine & Tobacco Research*, 4, 149–159.
- 1264 Strong, D. R., Brown, R. A., Kahler, C. W., Lloyd-Richardson,
1265 E. E., & Niaura, R. (2004). Depression proneness in
1266 treatment-seeking smokers: A taxometric analysis. *Person-*
1267 *ality and Individual Differences*, 36, 1155–1170.
- 1268 Thorndike, F. P., Friedman-Wheeler, D. G., & Haaga, D. A. F.
1269 (2006). Effect of cognitive behavior therapy on smokers'
1270 compensatory coping skills. *Addictive Behaviors*, 31,
1271 1705–1710.
- 1272 United States Department of Health and Human Services,
1273 (2008, May). *Clinical Practice Guideline: Treating tobacco*
1274 *use and dependence: 2008 update*. Retrieved April 26, 2010,
1275 from <http://www.surgeongeneral.gov/tobacco/index.html>
- 1276 Ziedonis, D., Hitsman, B., Beckham, J. C., Zvolensky, M.,
1277 Adler, L. E., Audrain-McGovern, J., Breslau, N., Brown,
1278 R. A., George, T. P., Williams, J., Calhoun, P. S., & Riley,
1279 W. T. (2008). Tobacco use and cessation in psychiatric
1280 disorders: National Institute of Mental Health report.
1281 *Nicotine & Tobacco Research*, 10(12), 1–25.

RECEIVED: June 18, 2009 1282
ACCEPTED: October 22, 2009 1283